Efficacy and Safety of Saxagliptin as Add-On Therapy in Type 2 Diabetes

Efficacy and Safety of Saxagliptin as Add-On Therapy in Type 2 Diabetes

Combination therapy for type 2 diabetes using agents with complementary mechanisms of action may improve glycemic control to a greater extent than monotherapy and allow the use of lower doses of antihyperglycemic medications. Dipeptidyl peptidase-4 inhibitors, including saxagliptin, are recommended...

Full description

Bibliographic Details
Main Author:	Neumiller, Joshua J.
Format:	Online
Language:	English
Published:	American Diabetes Association 2014
Online Access:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4220591/

Similar Items

Long-term safety and tolerability of saxagliptin add-on therapy in older patients (aged ≥65 years) with type 2 diabetes
by: Iqbal, Nayyar, et al.
Published: (2014)

Saxagliptin Efficacy and Safety in Patients With Type 2 Diabetes and Moderate Renal Impairment
by: Perl, Shira, et al.
Published: (2016)

Utility of Saxagliptin in the Treatment of Type 2 Diabetes: Review of Efficacy and Safety
by: Jain, Rajeev
Published: (2015)

Efficacy and safety of vildagliptin, Saxagliptin or Sitagliptin as add-on therapy in Chinese patients with type 2 diabetes inadequately controlled with dual combination of traditional oral hypoglycemic agents
by: Li, Chun-Jun, et al.
Published: (2014)

The Efficacy and Safety of Saxagliptin When Added to Metformin Therapy in Patients With Inadequately Controlled Type 2 Diabetes With Metformin Alone
by: DeFronzo, Ralph A., et al.
Published: (2009)

Overview of saxagliptin efficacy and safety in patients with type 2 diabetes and cardiovascular disease or risk factors for cardiovascular disease
by: Toth, Peter P
Published: (2014)

Effects of saxagliptin add-on therapy to insulin on blood glycemic fluctuations in patients with type 2 diabetes: A randomized, control, open-labeled trial
by: Li, Feng-fei, et al.
Published: (2016)

Treatment of type 2 diabetes with saxagliptin: a pharmacoeconomic evaluation in Argentina
by: Elgart, Jorge F, et al.
Published: (2013)

The Efficacy and Safety of Imeglimin as Add-on Therapy in Patients With Type 2 Diabetes Inadequately Controlled With Metformin Monotherapy
by: Fouqueray, Pascale, et al.
Published: (2013)

Effects of saxagliptin on early microvascular changes in patients with type 2 diabetes
by: Ott, Christian, et al.
Published: (2014)

Clinical utility in the treatment of type 2 diabetes with the saxagliptin/metformin fixed combination
by: Panagoulias, George S, et al.
Published: (2014)

Profile of saxagliptin in the treatment of type 2 diabetes: focus on Japanese patients
by: Konya, Hiroyuki, et al.
Published: (2014)

Saxagliptin for the treatment of type 2 diabetes mellitus: assessing cardiovascular data
by: Cobble, Michael E, et al.
Published: (2012)

Saxagliptin and Metformin in Fixed Combination for the Treatment of Type 2 Diabetes in Adults
by: Minze, Molly G., et al.
Published: (2013)

Empagliflozin: a new sodium-glucose co-transporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes
by: Neumiller, Joshua J
Published: (2014)

Nonclinical and clinical pharmacology evidence for cardiovascular safety of saxagliptin
by: Pia S. Pollack, et al.
Published: (2017-09-01)

Assessment of the cardiovascular safety of saxagliptin in patients with type 2 diabetes mellitus: pooled analysis of 20 clinical trials
by: Iqbal, Nayyar, et al.
Published: (2014)

Tolerability and efficacy of glycemic control with saxagliptin in older patients (aged ≥ 65 years) with inadequately controlled type 2 diabetes mellitus
by: Karyekar, Chetan S, et al.
Published: (2013)

Efficacy of Saxagliptin versus Mitiglinid in patients with type 2 diabetes and end-stage renal disease
by: Yukinao Sakai, et al.
Published: (2017-04-01)

The efficacy and safety of the dipeptidyl peptidase-4 inhibitor saxagliptin in treatment-naïve patients with type 2 diabetes mellitus: a randomized controlled trial
by: Frederich, Robert, et al.
Published: (2012)

Cost-Effectiveness of Saxagliptin versus Acarbose as Second-Line Therapy in Type 2 Diabetes in China
by: Gu, Shuyan, et al.
Published: (2016)

Alogliptin in combination with metformin and pioglitazone for the treatment of type 2 diabetes mellitus
by: Holland, Daniel Q, et al.
Published: (2014)

Sitagliptin as add-on therapy in insulin deficiency: biomarkers of therapeutic efficacy respond differently in type 1 and type 2 diabetes
by: Giampietro, Ottavio, et al.
Published: (2013)

Efficacy and Safety of Vildagliptin as Add-on to Metformin in Japanese Patients with Type 2 Diabetes Mellitus
by: Odawara, Masato, et al.
Published: (2014)

Efficacy and safety of add on low-dose mirtazapine in depression
by: Matreja, Prithpal S., et al.
Published: (2012)

Determinants of saxagliptin use among patients with type 2 diabetes mellitus treated with oral anti-diabetic drugs
by: Saine, M Elle, et al.
Published: (2015)

A randomized controlled trial of the efficacy and safety of twice-daily saxagliptin plus metformin combination therapy in patients with type 2 diabetes and inadequate glycemic control on metformin monotherapy
by: White, Judith L, et al.
Published: (2014)

Linagliptin as add-on therapy to insulin for patients with type 2 diabetes
by: von Websky, Karoline, et al.
Published: (2013)

Efficacy and safety of add on therapy of bromocriptine with metformin in Indian patients with type 2 diabetes mellitus: A randomized open labeled phase IV clinical trial
by: Ghosh, Arijit, et al.
Published: (2014)

Efficacy and safety comparison between liraglutide as add-on therapy to insulin and insulin dose-increase in Chinese subjects with poorly controlled type 2 diabetes and abdominal obesity
by: Li, Chun-jun, et al.
Published: (2012)

Saxagliptin: A dipeptidyl peptidase-4 inhibitor in the treatment of type 2 diabetes mellitus
by: Dave, Darshan J.
Published: (2011)

Comparison of adherence and persistence among adults with type 2 diabetes mellitus initiating saxagliptin or linagliptin
by: Farr, Amanda M, et al.
Published: (2016)

Testing the Therapeutic Equivalence of Alogliptin, Linagliptin, Saxagliptin, Sitagliptin or Vildagliptin as Monotherapy or in Combination with Metformin in Patients with Type 2 Diabetes
by: Messori, Andrea, et al.
Published: (2014)

The dipeptidyl peptidase-4 inhibitor Saxagliptin improves function of circulating pro-angiogenic cells from type 2 diabetic patients
by: Poncina, Nicol, et al.
Published: (2014)

Patient considerations and clinical utility of a fixed dose combination of saxagliptin/metformin in the treatment of type 2 diabetes
by: Derosa, Giuseppe, et al.
Published: (2011)

Saxagliptin: A Selective DPP-4 Inhibitor for the Treatment of Type 2 Diabetes Mellitus
by: Shubrook, Jay, et al.
Published: (2011)

Dipeptidyl Peptidase-4 Inhibition in Patients with Type 2 Diabetes Treated with Saxagliptin, Sitagliptin, or Vildagliptin
by: Tatosian, Daniel A., et al.
Published: (2013)

Comparison of charges and resource use associated with saxagliptin and sitagliptin
by: Vaidya, Varun, et al.
Published: (2016)

Efficacy and Safety of Vildagliptin as an Add-on to Insulin with or without Metformin in Japanese Patients with Type 2 Diabetes Mellitus: A 12-week, Double-Blind, Randomized Study
by: Hirose, Takahisa, et al.
Published: (2015)

Efficacy and safety of canagliflozin alone or as add-on to other oral antihyperglycemic drugs in Japanese patients with type 2 diabetes: A 52-week open-label study
by: Inagaki, Nobuya, et al.
Published: (2015)